Revlimid Approved With Safeguards Against Fetal Exposure
This article was originally published in The Pink Sheet Daily
Executive Summary
Education and prescribing safety program for Celgene’s Revlimid will restrict distribution and address risks of fetal exposure; the firm has ongoing studies to assess teratogenicity.